曲妥珠单抗联合微波热疗治疗HER-2阳性晚期乳腺癌的临床疗效分析  

Clinical efficacy of trastuzumab combined with microwave hyperthermia in treatment of HER-2 positive advanced breast cancer

作　　者：黄红莉 董桂玉 牛立志 Huang Hongli;Dong Guiyu;Niu Lizhi(PCR Lab,Fuda Cancer Hospital,Jinan University,Guangdong Guangzhou 510665,China;Pharmacy Department,the Sixth Affiliated Hospital of Sun Yat-sen University,Guangdong Guangzhou 510655,China)

机构地区：[1]暨南大学附属复大肿瘤医院PCR室,广东广州510665 [2]中山大学附属第六医院药剂科,广东广州510655

出　　处：《现代肿瘤医学》2020年第17期2985-2989,共5页Journal of Modern Oncology

基　　金：广东省省级科技计划项目(编号:2016A020216018)。

摘　　要：目的:探讨曲妥珠单抗联合微波热疗治疗HER-2阳性晚期乳腺癌患者的临床疗效。方法:选取我院2018年1月至2018年12月收治的HER-2阳性晚期乳腺癌患者54例,按随机表法分为治疗组与对照组,每组27例。两组均采用曲妥珠单抗治疗,治疗组同时给予微波热疗。比较两组患者免疫功能、循环肿瘤细胞(CTCs)、生存质量、近期疗效、总生存期及不良反应情况。结果:治疗组免疫功能和生存质量提高(P<0.05),CTCs数量下降(P<0.05);治疗组近期疗效及总生存期优于对照组(P<0.05);两组不良反应发生率比较差异无统计学意义(P>0.05)。结论:曲妥珠单抗联合微波热疗治疗HER-2阳性晚期乳腺癌患者具有良好的临床疗效且安全性较高。Objective:To investigate the clinical efficacy of trastuzumab combined with microwave hyperthermia in patients with HER-2 positive advanced breast cancer.Methods:Fifty-four patients with HER-2 positive advanced breast cancer admitted to our hospital from January 2018 to December 2018 were randomly divided into treatment group and control group,with 27 cases in each group.Both groups received trastuzumab and the treatment group received microwave hyperthermia.Immune function,circulating tumor cells(CTCs),quality of life,short-term efficacy,total survival and adverse effects were compared between the two groups.Results:In the treatment group,immune function and quality of life were improved(P<0.05),while the number of CTCs was decreased(P<0.05).The short-term efficacy and overall survival of the treatment group were better than that of the control group(P<0.05).The incidence of adverse effects in the two groups was not statistically significant(P<0.05).Conclusion:Trastuzumab combined with microwave hyperthermia in the treatment of HER-2 positive advanced breast cancer patients has good clinical efficacy and high safety.

关 键 词：曲妥珠单抗 微波热疗 HER-2阳性 晚期乳腺癌 临床疗效 

分 类 号：R737.9[医药卫生—肿瘤]